|Cell Metabolism||Tuesday, December 4, 2018||
The microenvironment influences cancer drug response and sustains resistance to therapies targeting receptor-tyrosine kinases. However, if and how the tumor microenvironment can be altered during...
|Lancet Oncology||Tuesday, September 11, 2018||
|Jci||Friday, August 31, 2018||
Cancer cell dependence on activated oncogenes is therapeutically targeted, but acquired resistance is virtually unavoidable. Here we show that the treatment of addicted melanoma cells with BRAF...
|Cancer Research||Sunday, July 1, 2018||
USP6NL, also named RN-tre, is a GTPase-activating protein involved in control of endocytosis and signal transduction. Here we report that USP6NL is overexpressed in breast cancer, mainly of the...
|Nature Communications||Tuesday, June 12, 2018||
Mariangela Russo, Simona Lamba, Annalisa Lorenzato, Alberto Sogari, Giorgio Corti, Giuseppe Rospo, Benedetta Mussolin, Monica Montone, Luca Lazzari, Sabrina Arena, Daniele Oddo, Michael...
|Science Translational Medicine||Tuesday, May 29, 2018||
Semaphoring to tumor vasculature
Solid tumors typically have blood vessels that are not only increased in number but also exhibit various structural and functional...
|Nature||Thursday, December 7, 2017||
Molecular alterations in genes involved in DNA mismatch repair (MMR) promote cancer initiation and foster tumour progression. Cancers deficient in MMR frequently show favourable prognosis and...
|Lancet Oncology||Tuesday, August 30, 2016||
Background: Cancer of unknown primary ranks in the top ten cancer presentations and has an extremely poor prognosis. Identification of the primary tumour and development of a tailored site-...
|Cancer Discovery||Monday, June 20, 2016||
A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR and BRAF inhibition with panitumumab plus vemurafenib. Pre-existing cells with increased MET gene copy...
|Sci Transl Med||Monday, February 29, 2016||